Silver Book

Silver Book Fact

Full medication coverage is expected to increase patient compliance from 50% to 76%. Expanded coverage would cost insurers an average of $644 more per patient, but would avert an average of $6,770 in event-related costs. Insurers would ultimately save $5,974 per patient.

Choudhry N, Avorn J, Antman E, Schneeweiss S, et al. Should Patients Receive Secondary Prevention Medications For Free After A Myocardial Infarction? An economic analysis. Health Affairs. 2007; 26(1): 186-194. https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.26.1.186?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed

Reference

Title
Should Patients Receive Secondary Prevention Medications For Free After A Myocardial Infarction? An economic analysis
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Choudhry N, Avorn J, Antman E, Schneeweiss S, et al.
Volume & Issue
Volume 26, Issue 1
Pages
186-194
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • TAVR v. SAVR in Intermediate-Risk SAS Patients
    At 1-year, severe aortic stenosis (SAS) patients with intermediate surgical mortality risk who underwent transcatheter aortic valve replacement (TAVR), had all-cause mortality rates of 7.4% (compared to 13% for surgical…  
  • Cost-savings associated with optimal anticoagulation in AFib patients
    If half of all atrial fibrillation patients receiving suboptimal or no anticoagulation instead received optimal anticoagulation, 28,000 strokes could be prevented each year at a savings of around $2.5 billion in direct…  
  • The projected economic value of eliminating deaths from stroke is $7.6 trillion.  
  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • Using technologies as treatment for heart disease helps generate cost savings, including a total of $1930 annual savings per person, and a $1.5 billion increased tax revenue